

U.K. NICE RECOMMENDS ANTICANCER AGENT HALAVEN® AS TREATMENT FOR ADVANCED BREAST CANCER

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its in-house developed anticancer agent Halaven® (eribulin mesylate, "eribulin") has been recommended by the U.K. National Institute for Health and Clinical Excellence (NICE) as a treatment for patients with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens for advanced disease (prior therapy may have included an anthracycline or a taxane, and capecitabine) in NICE's Final Appraisal Determination (FAD).¹ Eribulin is the first breast cancer treatment to be recommended by NICE since 2007.²

Following the issue of the FAD by NICE, eribulin will be eligible for reimbursement. 57.59 71((l)5(t)-6(l)5(He)-1050 1 89.064 542.59

[Notes to editors]

1. About Halaven (eribulin mesylate, “eribulin”)

Eribulin is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action. Structurally eribulin is a simplified and synthetically produced version of halichondrin B, a natural product isolated from the marine sponge *Halichondria okadai*. Eribulin is believed to work by inhibiting the growth phase of microtubule